세계의 히드론 치료 시장 예측(-2032년) : 입자 유형별, 컴포넌트별, 암 유형별, 최종사용자별, 지역별

According to Stratistics MRC, the Global Hadron Therapy Market is accounted for $2.1 billion in 2025 and is expected to reach $5.3 billion by 2032 growing at a CAGR of 13.6% during the forecast period. Hadron therapy is an advanced form of radiation treatment that uses charged particles like protons or carbon ions instead of conventional X-rays. These particles deliver highly targeted doses to tumors while minimizing damage to surrounding healthy tissue. Known for its precision and effectiveness, hadron therapy is particularly beneficial for treating deep-seated, radiation-resistant, or critical-area cancers. Its clinical potential is driving increasing investment in oncology and medical technology markets.

According to CNAO / MDPI reporting, over 290,000 patients have been treated with protons globally, with treatments increasing by more than 35,000 patients per year.

Market Dynamics:

Driver:

Rising global cancer prevalence

The continual rise in cancer incidence worldwide has markedly propelled the hadron therapy market. This trend is due to increasing numbers of patients seeking advanced and precise radiation therapies, with hadron therapy, especially proton and carbon ion modalities, emerging as highly effective options for complex and localized tumors. Additionally, the ongoing focus on precision medicine, combined with treatment-resistant cancer types, keeps up demand for more targeted treatments. The rapidly expanding cancer population globally ensures that the need for innovative oncological interventions, such as hadron therapy, will intensify, reinforcing market growth.

Restraint:

Limited number of treatment centers globally

The high capital investment required for constructing and operating hadron therapy centers severely limits their global distribution. These facilities demand extensive infrastructure, including cyclotrons or synchrotrons and robust radiation shielding, while also relying on a highly trained workforce. Complex regulatory approval processes and a lack of standardized reimbursement policies create additional hurdles, curtailing market penetration, particularly in emerging markets. Consequently, this scarcity restricts patient access and slows down the broader acceptance of hadron therapy worldwide, restraining market expansion.

Opportunity:

Integration of AI in treatment planning and imaging

AI-driven systems streamline repetitive and time-consuming processes, such as auto-segmentation of organs-at-risk and adaptive re-planning, resulting in more efficient workflows and reducing human variability. These advances enable clinicians to rapidly generate sophisticated, patient-specific treatment plans, boosting both the precision and confidence of therapy delivery. As AI technologies continue to evolve and gain regulatory approval, they promise not only operational efficiencies but also enhanced clinical outcomes for patients undergoing hadron therapy.

Threat:

High installation and operational costs

High installation and operational costs continue to act as formidable barriers, as establishing these facilities involves investments topping tens of millions of dollars due to the need for specialized equipment and rigorous building requirements. Ongoing expenses, such as expert staff salaries and maintenance of advanced technology, add further financial strain. These costs can make treatments prohibitively expensive for patients and challenge health insurers. These financial obstacles are expected to persist as a significant threat to sustained growth.

Covid-19 Impact:

The Covid-19 pandemic created a temporary setback for the hadron therapy market by disrupting healthcare delivery and shifting resources to pandemic response. Delays in the installation and commissioning of new centers occurred due to supply chain interruptions and travel restrictions, while routine treatments were postponed or slowed to accommodate infection control protocols. Patient access dwindled, particularly due to international travel limitations and resource allocation to critical care. However, despite these short-term disruptions, the hadron therapy sector has shown resilience, with a gradual return to regular operations as healthcare systems adapt and patient demand rebounds.

The proton therapy segment is expected to be the largest during the forecast period

The proton therapy segment is expected to account for the largest market share during the forecast period, attributed to its validated safety profile and ability to deliver highly targeted doses with minimal damage to surrounding tissues. Growing clinical evidence supports its superiority in reducing side effects, making it especially suitable for vulnerable populations such as pediatric patients and those with tumors near critical organs. Furthermore, expanded installation of proton therapy systems in leading hospitals and rising government support for non-invasive cancer care will solidify this segment's leadership position.

The pediatric cancer segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pediatric cancer segment is predicted to witness the highest growth rate, driven primarily by the heightened need for less toxic, more effective treatments for children, who are especially susceptible to long-term side effects from conventional radiation therapies. Increasing incidence rates of pediatric cancers worldwide, coupled with the push for clinical trial advancements and technological innovation in pediatric care protocols, are fueling this trend. Additionally, government grants and global health initiatives are further catalyzing the adoption of hadron therapy for pediatric oncology applications, generating robust growth prospects.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by its advanced healthcare infrastructure, strong research capabilities, and substantial public and private investments in cancer treatment technologies. The region benefits from early adoption of innovative therapies and established clinical networks, which facilitate widespread patient access. Additionally, the presence of leading equipment manufacturers and ongoing initiatives to expand hadron therapy facilities, particularly in the United States, ensure that North America remains at the forefront of clinical adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Investments in upgrading healthcare infrastructure, rising cancer prevalence, and heightened government and private sector funding underpin this surge. Japan and China are making significant inroads with state-of-the-art research hubs and newly established hadron centers, while India is emerging as a promising market owing to increased awareness and public-private partnerships. These efforts are fostering rapid adoption, making Asia Pacific the epicenter for future growth.

Key players in the market

Some of the key players in Hadron Therapy Market include Ion Beam Applications SA (IBA), Varian Medical Systems, Inc., Hitachi, Ltd., Mevion Medical Systems, Inc., Sumitomo Heavy Industries, Ltd., Mitsubishi Electric Corporation, Koninklijke Philips N.V., Advanced Oncotherapy PLC, Optivus Proton Therapy, Inc., Elekta AB, ProTom International, Inc., ProNova Solutions, LLC, Toshiba Energy Systems & Solutions Corporation, Provision Healthcare, LLC, Shinva Medical Instrument Co., Ltd., Danfysik A/S, and Siemens Healthineers AG.

Key Developments:

In June 2025, IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces the launch of Proton Therapy Academy, a new global training and education initiative developed in partnership with prominent institutions in the field of proton therapy. The Academy has been unveiled at the 2025 PTCOG (Particle Therapy Co-Operative Group) annual conference taking place in Buenos Aires, Argentina.

In January 2025, Mevion Medical Systems, the leader in compact proton therapy solutions, proudly announces the delivery of its first MEVION S250-FIT Proton Therapy System(TM)* to Stanford Health Care. This marks a significant milestone in the development of proton therapy, as it is the first time a full proton therapy system is to be installed in a room like a conventional linear accelerator (LINAC) vault. The new system represents a new frontier in proton therapy, integrating cutting-edge technology to enhance patient outcomes.

In December 2024, Mevion Medical Systems, a leading provider of compact proton therapy solutions, today announced that it has received approval from the National Medical Products Administration (NMPA) of China for its MEVION S250i Proton Therapy System. This marks the first time this advanced technology has been approved in China, making Mevion the first company to offer a compact, integrated proton solution to Chinese cancer patients.

Type of Particles Covered:

• Proton Therapy
• Carbon Ion Therapy
• Other Ion Therapy

Components:

• Equipment
• Software
• Services

Cancer Types Covered:

• Pediatric Cancer
• Prostate Cancer
• Head & Neck Cancer
• Lung Cancer
• Liver Cancer
• Breast Cancer
• Eye Cancer
• Bone & Soft Tissue Cancer
• Central Nervous System (CNS) Cancer
• Other Cancer Types

End Users Covered:

• Hospitals
• Dedicated Proton/Hadron Therapy Centers
• Research & Academic Institutions
• Private Oncology Clinics

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Hadron Therapy Market, By Type of Particle

• 5.1 Introduction
• 5.2 Proton Therapy
  • 5.2.1 Single-Room Systems
  • 5.2.2 Multi-Room Systems
• 5.3 Carbon Ion Therapy
• 5.4 Other Ion Therapy

6 Global Hadron Therapy Market, By Component

• 6.1 Introduction
• 6.2 Equipment
  • 6.2.1 Particle Accelerators
  • 6.2.2 Beam Delivery Systems
  • 6.2.3 Patient Positioning & Immobilization Systems
  • 6.2.4 Imaging Systems
• 6.3 Software
  • 6.3.1 Treatment Planning Software
  • 6.3.2 Patient Management Software
  • 6.3.3 Quality Assurance (QA) Software
• 6.4 Services
  • 6.4.1 Installation and Maintenance Services
  • 6.4.2 Training and Education
  • 6.4.3 Consulting Services

7 Global Hadron Therapy Market, By Cancer Type

• 7.1 Introduction
• 7.2 Pediatric Cancer
• 7.3 Prostate Cancer
• 7.4 Head & Neck Cancer
• 7.5 Lung Cancer
• 7.6 Liver Cancer
• 7.7 Breast Cancer
• 7.8 Eye Cancer
• 7.9 Bone & Soft Tissue Cancer
• 7.10 Central Nervous System (CNS) Cancer
• 7.11 Other Cancer Types

8 Global Hadron Therapy Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Dedicated Proton/Hadron Therapy Centers
• 8.4 Research & Academic Institutions
• 8.5 Private Oncology Clinics

9 Global Hadron Therapy Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Ion Beam Applications SA (IBA)
• 11.2 Varian Medical Systems, Inc.
• 11.3 Hitachi, Ltd.
• 11.4 Mevion Medical Systems, Inc.
• 11.5 Sumitomo Heavy Industries, Ltd.
• 11.6 Mitsubishi Electric Corporation
• 11.7 Koninklijke Philips N.V.
• 11.8 Advanced Oncotherapy PLC
• 11.9 Optivus Proton Therapy, Inc.
• 11.10 Elekta AB
• 11.11 ProTom International, Inc.
• 11.12 ProNova Solutions, LLC
• 11.13 Toshiba Energy Systems & Solutions Corporation
• 11.14 Provision Healthcare, LLC
• 11.15 Shinva Medical Instrument Co., Ltd.
• 11.16 Danfysik A/S
• 11.17 Siemens Healthineers AG